NasdaqGS:RVMDBiotechs
Can Revolution Medicines (RVMD) Get Any Less Expensive After Its Run?
Revolution Medicines has delivered a very strong share price run over the past few years, yet its valuation checks lean expensive. This sets up a clear tension between recent returns and what the broader metrics say about value.
Revolution Medicines has returned about 6.4x over the past 3 years. This places the stock in a very strong performance bracket and raises the bar for what future progress needs to justify.
The FDA review of daraxonrasib following positive survival data can support...